There was no statistical significance for disease-free survival between observation and receiving any type of adjuvant therapy following staging surgery.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background: Uterine carcinosarcoma is rare neoplasm that mostly presents as metastatic disease.
📊
Key Findings & Data:Stage is one of the most important prognostic factor, however, the management of the early stage uterine carcinosarcoma is still controversial.Aims: To evaluate prognostic factors, treatment options, and survival outcomes in patients with surgically approved stage I uterine carcinosarcoma.Study Design: Cross-sectional study.Methods: Data of 278 patients with uterine carcinosarcoma obtained from four gynecologic oncology centers were reviewed, and 70 patients with approved stage I uterine carcinosarcoma after comprehensive staging surgery were studied.Results: The median age of the entire cohort was 65 years (range; 39-82).
💡
Conclusion & Impact:There was no statistical significance for disease-free survival between observation and receiving any type of adjuvant therapy following staging surgery.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Background: Uterine carcinosarcoma is rare neoplasm that mostly presents as metastatic disease. Stage is one of the most important prognostic factor, however, the management of the early stage uterine carcinosarcoma is still controversial.Aims: To evaluate prognostic factors, treatment options, and survival outcomes in patients with surgically approved stage I uterine carcinosarcoma.Study Design: Cross-sectional study.Methods: Data of 278 patients with uterine carcinosarcoma obtained from four gynecologic oncology centers were reviewed, and 70 patients with approved stage I uterine carcinosarcoma after comprehensive staging surgery were studied.Results: The median age of the entire cohort was 65 years (range; 39-82). All patients underwent both pelvic and paraaortic lymphadenectomy. Forty-one patients received adjuvant therapy. The median follow-up time was 24 months (range; 1-129). Nineteen (27.1%) patients had disease failure. The 3-year disease-free survival and cancer-specific survival of the entire cohort was 67% and 86%, respectively. In the univariate analysis, only age was significantly associated with disease-free survival (p=0.022). There was no statistical significance for disease-free survival between observation and receiving any type of adjuvant therapy following staging surgery. Advanced age (
🔖
Cite This Article
TAŞKIN, S., ÖZGÜL, N., YÜCE, K., SALMAN, M. C., CUYLAN, Z. F., KOYUNCU, K., TÜRKMEN, O., ORTAÇ, F., CÖMERT, G. K., ALTIN, D., TURAN, T., BAŞARAN, D., BOYRAZ, G., KARALÖK, A., YALÇIN, İ., MEYDANLI, M. M., ŞAHİN, H. (2022). Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study. Balkan Medical Journal, Cilt: 36 - Sayı: 4, 229–234. https://ajindex.com/articles/461003
D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116:131-9.
Leath CA, Numnum TM, Kendrick JE, Frederick PJ, Rocconi RP, Conner MG, et al. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 2009;19:888-91.
Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer 2015;25:279-87.
Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2001;83:268-70.
Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. Am J Clin Oncol 2018;41:784-91.
Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH, et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol 2015;139:84-9.
Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol 2017;145:78-87.
Seagle BL, Kanis M, Kocherginsky M, Strauss JB, Shahabi S. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. Gynecol Oncol 2017;145:71-7.
Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol 2012;127:22-6.
Garg G, Yee C, Schwartz KL, Mutch DG, Morris RT, Powell MA. Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis. Gynecol Oncol 2014;133:242-9.
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18.
Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493-8.
Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A, et al.